What is MucoLyx NAC 600 mg?

MucoLyx NAC 600 mg is an N-acetylcysteine capsule formulation from Amplify Pharma.

N-acetylcysteine, commonly abbreviated as NAC, is the N-acetyl derivative of the amino acid L-cysteine. NAC has been used clinically for decades and has been extensively studied for its mucolytic properties, respiratory applications and role in the glutathione system.

Each MucoLyx capsule contains

What is N-Acetylcysteine (NAC)?

N-acetylcysteine is a cysteine-containing compound with a reactive sulfhydryl (-SH) group.

Its biological properties are related to several mechanisms, including its ability to reduce disulfide bonds in mucus and its contribution to cysteine availability for glutathione synthesis.

NAC has been investigated extensively in respiratory medicine and has also been studied in a range of conditions involving oxidative stress and altered redox balance.

How Does NAC Work?

N-acetylcysteine has two particularly important biological roles relevant to respiratory medicine.

1. Mucolytic action

Respiratory mucus contains mucin glycoproteins that are stabilized by disulfide bonds.

The sulfhydryl group of NAC can interact with these disulfide bonds, helping reduce the cross-linking within mucus and thereby lowering mucus viscosity and elasticity. This can facilitate the clearance of thick respiratory secretions.

NAC → Disulfide bond reduction → Reduced mucus viscosity → Easier mucus clearance

The mucolytic mechanism of NAC has been recognized for decades and remains one of its principal pharmacological properties.

2. Cysteine and glutathione availability

NAC can provide cysteine, which is an important substrate for the synthesis of glutathione (GSH).

Glutathione is a major intracellular thiol and contributes to cellular redox regulation and antioxidant defence.

The relationship can be summarized as:

MucoLyx NAC → Cysteine availability → Glutathione synthesis → Redox defence

However, NAC's biological effects should not be attributed solely to glutathione replenishment. Research indicates that NAC has several context-dependent mechanisms of action, including thiol chemistry and redox-related pathways.

NAC and Respiratory Health

N-acetylcysteine has been extensively studied in respiratory diseases, particularly conditions associated with mucus hypersecretion, impaired mucus clearance and recurrent exacerbations.

Its clinical role has been evaluated in:

• Chronic obstructive pulmonary disease (COPD)

• Chronic bronchitis

• Non-cystic fibrosis bronchiectasis

• Cystic fibrosis

• Acute exacerbations of COPD

• Other respiratory conditions

The clinical evidence varies according to the condition, patient phenotype, dose and duration of treatment. NAC should therefore be used according to the specific clinical indication and healthcare professional guidance.

NAC in COPD

COPD is characterized by persistent respiratory symptoms and airflow limitation. Patients with chronic bronchitis phenotype may have increased mucus production and impaired mucus clearance.

Clinical studies have evaluated NAC for its mucolytic and other biological effects in COPD.

The 2026 NECTAR evidence-based consensus document reviewed randomized trials, systematic reviews and expert consensus regarding NAC in respiratory diseases. The expert panel identified a role for NAC as an adjunct in stable COPD, particularly in patients with chronic bronchitis phenotype and frequent exacerbations.

The consensus-recommended dose for prevention of acute exacerbations in appropriate patients with stable COPD was:

NAC 600 mg twice daily

with the panel noting that optimal clinical benefit may require sustained treatment over several months.

Clinical decisions should take into account the patient's COPD phenotype, exacerbation history, airflow limitation, concurrent treatment and applicable guidelines.

NAC During Acute Exacerbations of COPD

NAC has also been evaluated as an adjunctive treatment during acute exacerbations of COPD.

The 2026 NECTAR consensus reported that oral NAC may contribute to symptom management and early recovery during an acute exacerbation, while emphasizing that NAC should be used alongside standard guideline-directed treatment, rather than as a replacement for bronchodilators, corticosteroids or other appropriate therapies.

The consensus recommended 600 mg/day of oral NAC during an acute exacerbation in its expert recommendations.

NAC in Bronchiectasis

Bronchiectasis is associated with abnormal airway dilation, impaired mucus clearance and recurrent respiratory infections.

NAC has been investigated for its mucolytic, antioxidant and other biological properties in non-cystic fibrosis bronchiectasis.

The 2026 NECTAR consensus concluded that NAC may be considered in patients with non-cystic fibrosis bronchiectasis who experience frequent exacerbations, while acknowledging that additional robust evidence is required. The expert panel supported a dose of 600 mg twice daily in this setting.

NAC should be considered as part of an overall bronchiectasis management strategy rather than as a substitute for airway-clearance techniques or other appropriate treatment.

NAC and Glutathione

Glutathione is an important intracellular antioxidant and thiol-containing molecule.

Cysteine availability can influence glutathione synthesis, and NAC has therefore been extensively studied as a cysteine source and glutathione precursor.

The relationship can be represented as:

NAC
↓
Cysteine availability
↓
Glutathione synthesis
↓
Cellular redox defence

NAC may also exert biological effects that are independent of simply increasing glutathione concentrations. Current research describes additional thiol- and sulfur-related mechanisms that may contribute to its biological activity.

NAC and Oxidative Stress

Oxidative stress occurs when the production of reactive molecules exceeds the capacity of cellular protective systems to maintain redox balance.

Because NAC contains a reactive thiol group and can contribute to cysteine availability, it has been extensively investigated in oxidative stress-related conditions.

Research has examined NAC's:

• Glutathione-related effects

• Thiol chemistry

• Redox activity

• Mucolytic properties

• Anti-inflammatory pathways

• Potential cytoprotective effects

The clinical relevance of these mechanisms varies considerably by disease and should not be interpreted as evidence that NAC is universally effective for every oxidative-stress-related condition.

MucoLyx NAC 600 mg: Key Features

MucoLyx NAC 600 mg provides:

• 600 mg N-acetylcysteine per capsule

• Convenient oral capsule dosage form

• HPMC capsule shell

• A clinically established NAC ingredient

• Mucolytic activity associated with disulfide-bond reduction in mucus

• Cysteine availability for glutathione synthesis

• A formulation from Amplify Pharma

Why Choose MucoLyx NAC 600 mg?

MucoLyx provides a clearly defined 600 mg NAC dose in capsule form.

The product is designed around the established pharmacological properties of N-acetylcysteine, including:

Mucolytic activity
↓
Mucus viscosity reduction

Cysteine availability
↓
Glutathione synthesis

Thiols and redox biology
↓
Cellular antioxidant defence

MucoLyx is intended to provide a convenient oral NAC formulation for use according to the relevant clinical indication and healthcare professional guidance.

Suggested Use

Use MucoLyx NAC 600 mg according to the recommendation of a healthcare professional.

The appropriate dose and duration depend on the clinical indication, patient characteristics, concomitant treatment and treatment objectives.

For respiratory conditions, dosing should follow the applicable clinical recommendation or prescribing information.

Do not alter the prescribed dose or duration without consulting a healthcare professional.

Safety and Precautions

N-acetylcysteine is generally well tolerated when used appropriately.

Possible adverse effects can include:

• Nausea

• Vomiting

• Abdominal discomfort

• Diarrhoea

• Headache

Individuals with relevant medical conditions, a history of hypersensitivity to NAC, or those taking prescription medicines should consult a healthcare professional before use.

Any unexpected or significant adverse reaction should be discussed with a healthcare professional.

Frequently Asked Questions

What is MucoLyx NAC 600 mg?

MucoLyx NAC 600 mg is an oral capsule containing 600 mg of N-acetylcysteine (NAC) per capsule. It is a product of Amplify Pharma.

What is N-acetylcysteine?

N-acetylcysteine, or NAC, is a cysteine-containing compound with established mucolytic activity. It can also provide cysteine for glutathione synthesis.

What is MucoLyx NAC 600 mg used for?

N-acetylcysteine is used and studied primarily for its mucolytic properties and has been investigated extensively in respiratory diseases including COPD and bronchiectasis.

The appropriate use depends on the specific clinical indication and should be determined by a healthcare professional.

How much NAC is in MucoLyx?

Each MucoLyx NAC 600 mg capsule contains 600 mg of N-acetylcysteine.

Is MucoLyx the same as N-acetylcysteine?

No.

MucoLyx is the brand name, while N-acetylcysteine (NAC) is the active ingredient.

MucoLyx contains 600 mg of N-acetylcysteine per capsule.

How does NAC help with mucus?

NAC contains a reactive sulfhydryl group that can reduce disulfide bonds within mucus glycoproteins. This can decrease mucus viscosity and support clearance of thick secretions.

Is NAC a glutathione precursor?

Yes. NAC can provide cysteine, an important substrate for glutathione synthesis. NAC has therefore been extensively studied as a precursor supporting the glutathione system.

What dose of NAC has been studied in COPD?

Dose depends on the clinical situation. The 2026 NECTAR consensus recommends 600 mg twice daily for prevention of exacerbations in appropriate patients with stable COPD, particularly chronic bronchitis phenotypes and frequent exacerbators.

Can NAC be used during an acute COPD exacerbation?

The 2026 NECTAR consensus considers oral NAC an adjunctive option during acute exacerbations, with an expert recommendation of 600 mg/day, alongside standard COPD treatment.

Is NAC recommended for everyone with COPD?

Not necessarily. The role of NAC depends on the patient's phenotype, exacerbation history, airflow limitation and other clinical factors. The 2026 NECTAR consensus particularly supported its use in chronic bronchitis phenotypes and patients with frequent exacerbations.

Is NAC useful in bronchiectasis?

NAC has been studied in non-cystic fibrosis bronchiectasis. The 2026 NECTAR consensus states that NAC may be considered in patients with frequent exacerbations, while recognizing that additional evidence is needed.

What is the difference between NAC and glutathione?

NAC and glutathione are different compounds.

NAC can provide cysteine, which is required for the synthesis of glutathione. Glutathione itself is an important intracellular antioxidant and redox-regulating molecule.

Product Information

About Amplify Pharma

Amplify Pharma develops and markets pharmaceutical and nutraceutical products with a focus on evidence-based formulations and clinically relevant ingredients.

MucoLyx NAC 600 mg is part of the company's respiratory-health portfolio, providing N-acetylcysteine in a convenient 600 mg capsule formulation.

References and Clinical Evidence

1. Barne M, Shevade M, Bhattacharyya P, et al. N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). Frontiers in Medicine. 2026;13:1810363.

2. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine.Biochim Biophys Acta. 2013.

3. Rushworth GF, Megson IL. Existing and potential therapeutic applications of N-acetylcysteine. Clinical Science. 2014.

4. Samuni Y, et al. The mechanism of action of N-acetylcysteine: the emerging role of H2S and sulfane sulfur species. Pharmacology & Therapeutics. 2021.

5. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. European Respiratory Journal.

6. Cazzola M, et al. Clinical evidence regarding NAC and respiratory disease.

Important medical information

This page is intended to provide general product and scientific information. It is not a substitute for diagnosis or individualized medical advice. Product use, dosage and duration should be determined according to the applicable prescribing information and advice of a qualified healthcare professional.